Published Jun 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

Member News
Copy The Link to the  Article
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
Copy The Link to the  Article

Related or similar articles

View more News
January 23, 2025

Labshares Enters 2025 with Significant Momentum

Press Releases
March 26, 2019

Abcuro announces pre-clinical data on new immuno-oncology target

First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News
April 14, 2019

Global 3D Printed Drugs Market Insights 2019-2024 : Extend Biosciences, Bioduro, Affinity Therapeutics

One of the dominating players in the 3D Printed Drugs market is Extend Biosciences
Member News